Hosted on MSN7h
Scientists Make Groundbreaking Discovery in the Search for the Cause of Inflammatory Bowel Disease
In a major breakthrough, researchers in the UK have discovered a potential root cause of inflammatory bowel disease (IBD), a ...
ServiceNow, IBD Stock Of The Day, Focused On Growth Drivers Beyond AI
ServiceNow stock is the IBD Stock of the Day ahead of the enterprise software maker's fourth quarter earnings report.
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
clinicaltrialsarena1d
Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial
Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...
FDA approves Omvoh for moderately to severely active Crohn's disease
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...
health.economictimes.indiatimes1d
Webinar on Living with IBD and choosing the right treatment
Inflammatory Bowel Disease (IBD) is a term for chronic inflammatory conditions affecting the digestive tract, primarily Crohn ...
News Medical1d
Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency
Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...
San Francisco Examiner2d
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely ...
Healio2d
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
TMCnet2d
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 ...
Palisade Bio completes all five SAD cohorts, advanced MAD cohorts for PALI-2108
Bio announced the completion of all five planned Single Ascending Dose, SAD, cohorts and the commencement of the Multiple Ascending Dose ...
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment
Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...